Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever

Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the recent acceptance of an NDA for its lead ADHD candidate, CTx-1301. The company also announced a strengthened intellectual property portfolio, including a US Patent Notice of Allowance and additional grants in Europe for CTx-1301. These legal milestones recognize the unique capabilities of Cingulate’s proprietary Precision Timed Release/PTR platform, which is designed to deliver medication according to specific patient needs throughout the day.

Furthermore, the company recently closed a $12 million private placement at-the-market pricing to support its foundation. The CEO noted that this funding, combined with the addition of experienced commercial leadership, supports the company’s transition toward market readiness. While advancing through the FDA regulatory review process for CTx-1301, Cingulate is focusing on manufacturing scale-up to ensure it is positioned for a successful commercial launch upon potential approval.

Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever

The company’s strategy remains centered on using its PTR platform to develop a pipeline of next-gen products that address unmet needs in the biopharma space. The CEO emphasized that the progress made throughout 2025 has set a strong trajectory for 2026, with a focus on building long-term value for shareholders and patients alike. By securing its patent estate and strengthening its balance sheet, Cingulate Inc. (NASDAQ:CING) aims to provide a different treatment option for the ADHD market.

Cingulate Inc. (NASDAQ:CING) is a clinical-stage biotech company using its proprietary drug delivery platform to develop treatments for ADHD and anxiety. Its lead candidate, CTx-1301, is in Phase 3 trials for ADHD across all age groups, while its pipeline includes CTx-2103 for anxiety and plans for CTx-1302 to further address ADHD.

While we acknowledge the risk and potential of CING as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CING and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.